Clinical Trials Logo

Diabetes Mellitus clinical trials

View clinical trials related to Diabetes Mellitus.

Filter by:

NCT ID: NCT03671915 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 1

Diabeloop for Kids

DBL4K
Start date: November 2018
Phase: N/A
Study type: Interventional

An open-label, three-center, randomized, two-session, 4 days inpatient and 6-week follow-up home study phase, crossover study comparing Diabeloop closed-loop (CL) system and sensor-augmented pump (SAP) therapy. The follow-up home study phase will be done only in French centers for a sub study. During this session, patient wearing the closed-loop system will benefit of a 24h/24, 7 d/7, remote monitoring follow-up by specialized nurses, under supervision of a diabetologist. A visualization of glucose CGM curves, insulin delivery, meal and physical activity announcements will be available online through secured website, and the system will send automated message in case of predetermined situations as persistent too high or too low Blood Glucose (BG). Custom settings will be possible by the nurses during the follow-up period.

NCT ID: NCT03671161 Completed - Clinical trials for Diabetes Mellitus, Type 1

Flash Glucose Measure System and Continuous Subcutaneous Insulin Infusion Therapy in Poorly Controlled Diabetes Type 1 Patients

FREESTYLE
Start date: January 1, 2016
Phase: N/A
Study type: Interventional

Patients with diabetes type 1 with poor glycemic control will be switched to insulin pump and FGM system (Flash Glucose Monitoring) during 6 months, correlated to the hypothesis that they could benefit from this intervention by being reengaged in diabetes self-management.

NCT ID: NCT03670797 Not yet recruiting - Diabetes Clinical Trials

Prevalence Of Oral Mucosal Alterations In Diabetes Mellitus Type2

Start date: October 2018
Phase:
Study type: Observational

There are severe deficiency of database concerning the oral health status in Egyptian patients with Diabetes type 2. Our aim in the present study is to study the prevalence of oral mucosal alterations in type 2 DM patients and the effect of hyperglycemia on these alterations in controlled and uncontrolled patients to increase their awareness and minimize all the possible risk factors,to achieve a proper management for all oral problems.

NCT ID: NCT03670641 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Remission Through Early Monitored Insulin Therapy - Duration Month

REMIT-DM
Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

REMIT-DM is a feasibility pilot study where participants will be recruited soon after their diagnosis of type 2 diabetes to be placed immediately on insulin therapy for maximum of four weeks with titrations of insulin guided by glucose levels and trends provided by a continuous glucose monitor (CGM), with the purpose of achieving diabetes remission.

NCT ID: NCT03670043 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

Tolerance & Responsiveness Improvement for Metformin (TRIM)

Start date: November 2018
Phase: Phase 4
Study type: Interventional

The overall goal is to explore the hypothesis that prebiotic fiber Psyllium will ameliorate diarrhea in African American men (AAM) with Type2 Diabetes Mellitus (T2D).

NCT ID: NCT03669887 Recruiting - Diabetes Clinical Trials

RCT of Lifestyle Modification to Improve Diet in Women With GDM

Start date: September 12, 2018
Phase: N/A
Study type: Interventional

The study aims to adapt a lifestyle modification program to engage GDM women early in the postnatal period to evaluate its effectiveness in reducing adiposity and metabolic parameters in the mother. Women will be randomized to receive a structured intervention or standard care.

NCT ID: NCT03669770 Completed - Clinical trials for Type 1 Diabetes Mellitus

Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes

TITANIC
Start date: September 22, 2017
Phase:
Study type: Observational [Patient Registry]

This study will use ultrasound to characterise lipohypertrophy(LH) and assess the impact of LH on glucose variability in adults with type 1 diabetes. LH is a condition that occurs with repeated exposure to insulin at injection sites, resulting in the development of subcutaneous fatty lumps that impede the absorption of insulin. LH can lead to glucose variability, increased risk of severe hypoglycaemia and diabetes distress. In the long term it can therefore lead to increased risk of diabetes complications and increased insulin costs.

NCT ID: NCT03668808 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 1

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.

SafrTravlT1D
Start date: September 2018
Phase: Phase 4
Study type: Interventional

The purpose of the proposed study is to compare insulin Degludec [TRESIBA® (insulin degludec injection)] with insulin Glargine U100 [Lantus® (insulin glargine injection)] to determine the basal insulin of choice for adults with type 1 diabetes (T1D) who fly non-stop across multiple time zones. With the introduction of Degludec as basal insulin for T1D and the opportunity to vary time of injection between 8 and 40 hours, the use of Degludec as a basal insulin may make it easier for both people living with T1D and diabetologists to plan long-haul travel compared to the use of existing basal insulins when crossing multiple time zones.The study hypothesis is that once daily Degludec as the basal insulin will provide better glycemic control for people with type 1 diabetes on multiple daily injections who are traveling non-stop across multiple time zones than once daily Glargine U100.

NCT ID: NCT03668470 Not yet recruiting - Clinical trials for Adult Subjects With Type1Diabetes and Insulin Microsecretion

Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes

DIAMOND GLP1
Start date: October 2018
Phase: Phase 2
Study type: Interventional

Some patients with type 1 diabetes (T1D) can still have some remaining insulin-positive cells in the pancreas and secrete little amounts of insulin. Despite the presence of residual beta cells, the HbA1C levels remain at high levels due to functional defects of insulin secretion associated with glucotoxicity. Previous trials have indicated that treatment with a Glucagon-like peptide 1 (GLP-1 )receptor agonist in T1D with some residual beta-cell function might improve glycemic control, reduce dose of insulin and risk of hypoglycemia. The general hypothesis of DIAMOND-GLP1 is that GLP1-R agonists will improve blood glucose After initial screening to select insulin microsecretors and a run-in period of one month, patients will be randomized into two arms and followed in parallel for 24 weeks : - Experimental group receiving 1.5 mg Dulaglutide s.c weekly in addition to their usual insulin regimen - Control group receiving placebo s.c weekly in addition to their usual insulin regimen. The primary endpoint is HbA1c value at 24 weeks

NCT ID: NCT03668301 Completed - Clinical trials for Diabetes Mellitus (D003920)

Cerebral-tissue Oxygen Balance Affected by Diabetes Mellitus

Start date: January 2017
Phase:
Study type: Observational

The brain has high oxygen extraction, thus the regional cerebral tissue oxygen saturation (rSO2) is lower than the central venous oxygen saturation (ScvO2). We hypothesized that diabetes widens the physiological saturation gap between ScvO2 and rSO2 (gSO2), and the width of this gap may vary during various phases of cardiac surgery. We involve cardiac surgery patients with and without type 2 diabetes mellitus (T2DM) undergoing either off-pump coronary artery bypass (OPCAB) or other cardiac surgery necessitating cardiopulmonary bypass (CPB). rSO2 is measured by near-infrared spectroscopy (NIRS) and ScvO2 is determined simultaneously from central venous blood. rSO2 is registered before and after anesthesia induction and at different stages of the surgery.